Treatment with tenofovir disoproxil fumarate or entecavir in chronic hepatitis B virus‐infected patients with renal impairment: results from a 7‐year, multicentre retrospective cohort study

BACKGROUND: Limited data exist regarding tenofovir disoproxil fumarate (TDF) safety and effectiveness in chronic hepatitis B virus–infected (CHB) patients with renal impairment (RI). AIMS: To compare real‐world data on renal safety and effectiveness of TDF vs entecavir (ETV) in CHB patients with mod...

Descripción completa

Detalles Bibliográficos
Autores principales: Lampertico, Pietro, Berg, Thomas, Buti, Maria, Pathil, Anita, Petersen, Joerg, Ryder, Stephen D., Zoulim, Fabien, Botros, Irina, Flaherty, John F., Jump, Belinda, Op den Brouw, Marjoleine L., van Troostenburg, Anna, Ramroth, Heribert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Treatment of Hbv Infection in Patients with Renal Impairment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7383725/
https://www.ncbi.nlm.nih.gov/pubmed/32583915
http://dx.doi.org/10.1111/apt.15901

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7383725/
https://www.ncbi.nlm.nih.gov/pubmed/32583915
http://dx.doi.org/10.1111/apt.15901

Ejemplares similares